J&J Stakes Claim For Growing Obesity And Diabetes Markets
This article was originally published in The Gray Sheet
Executive Summary
The growing global incidence of obesity and diabetes is attracting attention from Johnson & Johnson, which says it will target the markets more aggressively with comprehensive strategies that gather resources from across the company's devices, pharmaceutical and consumer products businesses
You may also be interested in...
J&J's Vitros Lab Diagnostics Systems Expand Market Access, Drive Sales
Ortho-Clinical Diagnostics' Vitros 5600 and Vitros 3600 next-generation laboratory diagnostic systems will double the size of the market the Johnson & Johnson division addresses from $4.6 billion to $9.8 billion, according to the company
J&J's Vitros Lab Diagnostics Systems Expand Market Access, Drive Sales
Ortho-Clinical Diagnostics' Vitros 5600 and Vitros 3600 next-generation laboratory diagnostic systems will double the size of the market the Johnson & Johnson division addresses from $4.6 billion to $9.8 billion, according to the company
Surgery For Diabetes? CMS Will Look At The Evidence For Coverage
In response to media attention focused on bariatric surgery's potential to send diabetes patients into remission, a skeptical CMS said last week that it would consider whether a new national Medicare coverage policy was needed